BforCure’s Post

Another fantastic Springer Nature Group / Nature Portfolio publication on the UK Biobank Pharma Proteomics Project (UKB-PPP): Proteomic signatures improve risk prediction for common and rare diseases https://lnkd.in/eF8KyEDM Identified #protein #signatures can #predict the #risk of developing more than 60 #diseases. Congratulations to the fist author Julia Carrasco Zanini Sanchez, last author Claudia Langenberg, and the team of equally contributing authors and co-authors for this success. This study has been facilitated by Olink Proteomics Proximity Extension Assay, #PEA #technology, allowing the measurement of thousands of proteins in just one drop of blood. With this powerful data set, protein signatures can now be validated in relevant #patient #cohorts from which #protein #signature custom panels can be developed to function as a #biomarker driven #prediction test. For the latter, Olink's PEA technology can be utilized by applying Olink® #Focus and #Flex reagents, going from brought screening panels to a targeted low-plex #clinical #application on one single technology platform. Gaining minimal invasive biomarker tests consuming only 1µL of plasma/serum during the lab workflow. https://lnkd.in/ekXQdW6u https://lnkd.in/ejihwcbE

🚀 Straight out of the Advanced Technologies for Drug Delivery lab at iMed.ULisboa, a new paper titled “Optimization and evaluation of a chitosan-coated PLGA nanocarrier for mucosal delivery of Porphyromonas gingivalis antigens” has just been #Published! 📚Recent advances in understanding Alzheimer's disease (AD) suggest the possibility of an infectious etiology, with Porphyromonas gingivalis emerging as a prime suspect in contributing to AD. P. gingivalis may invade systemic circulation via weakened oral/intestinal barriers and then cross the blood-brain barrier (BBB), reaching the brain and precipitating AD pathology. Based on the proposed links between P. gingivalis and AD, a prospective approach is the development of an oral nanovaccine containing P. gingivalis antigens for mucosal delivery. The present study describes the optimization, characterization, and in vitro evaluation of a candidate chitosan-coated poly(lactic-co-glycolic acid) (PLGA-CS) nanovaccine containing a P. gingivalis antigen extract. (Adapted from the Abstract.) 💥 Congratulations to the authors André Silva, Li­dia Goncalves, Adelaide Fernandes and Almeida Antonio! 🔎 You can read the full article here: https://lnkd.in/g6gue48c Keywords: #PorphyromonasGingivalis; #Nanovaccine; #PolyLacticCoGlycolicAcid); #Chitosan; #MucosalDelivery

You want to learn about Biomarkers in Redox medicine? RMS2024, June 27-28, 2024 (Fondation Biermans-Lapôtre – Paris) is the place to be. Day 1 - June 27, 2024 Keynote Speech: Redox Medicine 2024: Where we are now and where we are heading?   Session 1: Redox Balance in Health & Disease  - Discuss the mechanistic insights of redox balance.  - Explore the pivotal role of biomarkers in understanding disease mechanisms.  - Discover the interplay between biophysics, biology, and health. Session 2: Evaluation of Redox Status and Related Biomarkers  - Learn about cutting-edge methods, tools, AI applications, biosensors, and devices.  - Experience hands-on demonstrations alongside our industry partners. Round-table Discussion with the RMS Scientific Board: - Facilitating discussions on current challenges and opportunities in Redox Medicine. Day 2 - June 28, 2024: Session 3: The Future of Redox Medicine 2024: Innovative Directions and Emerging Trends - Biomarkers: Prevention and Diagnosis in Redox Medicine  - Uncover the potential of small synthetic, natural antioxidants, and redox molecules.  - Highlight the integration of AI, algorithms, and Redox Medicine.  - Examine the latest innovations and challenges related to iron, redox, and ferroptosis.  - Explore the emerging field of Skin Redoxome among other topics. Session 4: Redox Medicine from Bench to Bedside, Companion Diagnostics  - A collaborative session featuring insights from BioPharma, CRO, CDMO, and regulatory bodies. Concluding Remarks & Redox Medicine 2024 Awards. 👉 Save the Date: June 27-28, 2024. Stay tuned for more information on registration and program details on the RMS website: www.redox-medicine.com. #RedoxMedicine2024 #RedoxMedicineSociety #biomarkers #companiondiagnostics #RedoxBiology #MedicalResearch #InnovationInHealth #Redox #Antioxidants #biopharma #innovation

Kynurenine pathway and #transfusion related #Immunomodulation .(TRIM)...can this be the missing link ..needs more exploration.. #safeblood #rightblood #personalized #transfusionmedicine

🔬 Our Recent Paper on Protein Biomarker Detection is Now Live on 𝑵𝒂𝒏𝒐 𝑻𝒐𝒅𝒂𝒚! I'm humble to share that our latest paper, "Protein Biomarker Detection via Differential Dynamic Microscopy," has been published in Nano Today, a reputable journal in the field. Through our team's collaboration, we've advanced an innovative application of Differential Dynamic Microscopy (DDM) for disease diagnosis and monitoring. Our manuscript focuses on quantifying SARS-CoV-2 antibodies as a protein biomarker model, highlighting DDM's benefits of simple sample preparation, versatility, and rapidity. This approach shows promise for laboratories, especially in remote areas with limited resources. Additionally, miniaturizing the imaging setup could facilitate point-of-use applications. I'm grateful for the expertise of my supervisor, Prof. xavier Banquy, and all the other co-authors, especially Pierre-Luc Latreille and Marine Le Goas, whose contributions were essential to this project. 💡 You can find the full paper here: https://lnkd.in/e9kkasCv #Immunoassay #COVID19 #Bead-based #protein #corona #Matrix-effects #Antibody #Fluorescence #NanoToday

Source: International journal of molecular sciences Mass spectrometry (MS) is vital for biomolecule analysis, enhancing biomarker discovery and personalized medicine. Coupled with liquid chromatography (LC), MS identifies disease biomarkers and quantifies biomolecules for diagnostics and prognosis. Its precision aids in understanding disease mechanisms and tailoring patient treatments. High-resolution and integrated MS technologies improve detection of low-abundance molecules and complex pathways, driving innovations in individualized patient care and disease management.

The article "Extracellular vesicles as tools and targets in therapy for diseases" by Kumar et al. discusses the therapeutic applications of extracellular vesicles, particularly exosomes, in treating various diseases byh exploring the potentials of how these vesicles can be used to targets diseases. The authors emphasize the role of exosomes as essential tools for delivering therapeutic cargo and modulating cellular functions, possessing a promising therapeutic potential, and explore the disease-specific applications of extracellular vesicles to address unmet medical needs. The article also dives into the intricate biological signaling mechanisms mediated by extracellular vesicles. By harnessing the unique properties of exosomes and leveraging their targeted therapeutic applications, Lumosa is at the forefront of developing precision medicines. Article link: https://lnkd.in/gAbfZa3B #Exosomes #MedicalInnovations #DrugDevelopment #Biotech

🎉New in #JEV 🎉 Evaluation of unmodified human cell-derived extracellular vesicle mitochondrial deoxyribonucleic acid-based biodistribution in rodents Recently, extracellular vesicles (EVs) have been developed as therapeutic targets for various diseases. Biodistribution is crucial for EVs intended for therapeutic purposes because it can determine the degree of on- and off-target effects. This study aimed to explore techniques to evaluate the biodistribution of unmodified EVs. The authors devised a novel quantitative polymerase chain reaction (qPCR)-based assay to detect unmodified EVs by targeting mitochondrial deoxyribonucleic acid (mtDNA), a constituent of EVs. They focused on specific mtDNA regions that exhibited homologous variations distinct from their rodent mtDNA counterparts to establish this analytical approach. Herein, they successfully designed primers and probes targeting human and rodent mtDNA sequences and developed a highly specific and sensitive qPCR method. Furthermore, the quantification range of EVs isolated from various cells differed based on the manufacturer and cell source. IRDye 800CW-labelled Expi293F EV mimetics were administered to the animals via the tail vein to compare the imaging test and mtDNA-qPCR results. The results obtained from imaging tests and mtDNA-qPCR to investigate EV biodistribution patterns revealed differences. The results revealed that this newly developed method effectively determined the biodistribution of unmodified EVs with high sensitivity and reproducibility. https://lnkd.in/eww_7aZ5

Journey of Innovation continues......

A fluid biomarker for early detection of ALS and FTD Research studies have repeatedly shown that in patients with ALS or FTD, the function of TAR DNA-binding protein 43, more commonly called TDP-43, becomes corrupted. When this happens, pieces of the genetic material called ribonucleic acid (RNA) can no longer be properly spliced together to form the coded instructions needed to direct the manufacture of other proteins required for healthy nerve growth and function. The RNA strands become riddled with erroneous code sequences called “cryptic exons” that instead affect proteins believed to be associated with increased risk for ALS and FTD development. Until now, it was unknown if this abnormality occurred early or late in the clinical courses of ALS and FTD. In a study in the journal Nature Medicine, the researchers tell how they answered that long-pondered question. “We developed a method for locating a specific cryptic exon-linked protein, hepatoma-derived growth factor-like 2 [HDGFL2], that is associated with the loss of TDP-43’s function,” says the senior study author. “By doing so, we believe we’ve discovered a biomarker that could potentially be used to detect ALS and FTD in their earliest stages — even before symptoms appear.” #ScienceMission #sciencenewshighlights https://lnkd.in/gFb5FeyP